Neurocrine Biosciences, Inc. (NBIX)

業務介紹

紐羅克萊恩生物科學公司發現、開發和銷售用於神經、內分泌和精神疾病的藥物。該公司的產品組合包括治療遲發性肌動症、帕金森病、子宮內膜異位症和子宮肌瘤的治療方法,以及在各種治療領域的臨床項目。其主要資產是INGREZZA,一種VMAT2抑制劑,用於治療遲發性肌動症。該公司的商業產品包括ONGENTYS,一種卡替考爾-O-甲基轉移酶抑制劑,用作帕金森病患者levodopa/DOPA脫羧酶抑制劑的輔助療法;ORILISSA,用於管理中度至重度子宮內膜異位症引起的疼痛;以及ORIAHNN,一種非手術口服藥物選擇,用於管理閱前婦女子宮肌瘤相關的月經過多。其臨床開發中的產品候選藥物包括NBI-921352,用於治療兒童患者以及成人局灶性癲癇適應症;NBI-827104,用於治療罕見的兒童癲癇和必需性震顫。該公司臨床開發中的產品還包括NBI-1065845,用於治療重度抑鬱症;NBI-1065846,用於治療重度抑鬱症中的快感缺失;以及NBI-118568,用於治療精神分裂症。它與Heptares Therapeutics Limited、武田藥品工業株式會社、Idorsia Pharmaceuticals Ltd、Xenon Pharmaceuticals Inc.、Voyager Therapeutics, Inc.、BIAL Portela & Ca, S.A.、三菱丹波製藥株式會社和AbbVie Inc.有許可和合作協議。紐羅克萊恩生物科學公司成立於1992年,總部位於加利福尼亞州聖地亞哥。



Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

公司網址

https://www.neurocrine.com